Open Access<p>Pseudo-Progression and the Neutrophil-to-Lymphocyte Ratio in Non-Small Cell Lung Cancer Treated with Immune Checkpoint Inhibitors: A Case–Control Study</p>
Author(s) -
Tatsunori Kiriu,
Masatsugu Yamamoto,
Tatsuya Nagano,
Daisuke Hazama,
Reina Sekiya,
Masahiro Katsurada,
Naoko Katsurada,
Motoko Tachihara,
Kazuyuki Kobayashi,
Yoshihiro Nishimura
Publication year - 2019
Publication title -
oncotargets and therapy
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.054
H-Index - 60
ISSN - 1178-6930
DOI - 10.2147/ott.s228138
Subject(s) - neutrophil to lymphocyte ratio , medicine , lung cancer , immune system , immunology , lymphocyte , cancer research , oncology
Pseudo-progression (PsPD) is a rare phenomenon observed in <5% of cases of non-small cell lung cancer (NSCLC). This event is challenging for both clinicians and patients. Viable biomarkers to distinguish between PsPD and true progressive disease (TPD) are lacking. The aim of our study was to determine the correlation between PsPD and the neutrophil-to-lymphocyte ratio (NLR) in patients with NSCLC treated with immune checkpoint inhibitors (ICIs).